No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
<p>Abstract</p> <p>Background</p> <p>The mechanisms of chemoresistance in ovarian cancer patients remain largely to be elucidated. Paclitaxel/cisplatin combination is the standard chemotherapeutic treatment for this disease, although some patients do not respond to ther...
Main Authors: | Pinto Carla, Pinto Isabel M, Tavares Ana, Pereira Deolinda, Veiga Isabel, Mesquita Bárbara, Teixeira Manuel R, Castedo Sérgio |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2005-08-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/5/101 |
Similar Items
-
Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas.
by: Bicknell, D, et al.
Published: (1996) -
Knockout of vasohibin‐2 reduces tubulin carboxypeptidase activity and increases paclitaxel sensitivity in ovarian cancer
by: Takahiro Koyanagi, et al.
Published: (2021-04-01) -
Transcription and mismatch repair in the mechanism of action of the anticancer drug cisplatin
by: Mello, Jill Ann, 1966-
Published: (2008) -
First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence
by: Sandercock, J, et al.
Published: (1998) -
Mismatch repair and treatment resistance in ovarian cancer
by: van der Burg Maria EL, et al.
Published: (2006-07-01)